Sleuthinsights

Proprietary therapeutic-class pipeline and commercial-performance database, refreshed to a stated as-of date (August 2026): every active program in a class is catalogued and classified by development stage (343 preclinical / 14 IND / 95 Phase 1-1/2 / 51 Phase 2-2/3 / 51 Phase 3 / 24 filed / 50 approved), by developer headquarters country, by mechanism with a target-pairing taxonomy (124 unique combination pairings), by route of administration (injectable vs oral), and by indication expansion (181 cardio-renal-metabolic incretin programs), then joined to disclosed brand-level product sales (Mounjaro $18.6bn, Zepbound $9.1bn, Ozempic $9.3bn, Wegovy $5.9bn, Wegovy pill $855m, Foundayo $98m for H1 2026), innovation-vs-biosimilar flags, licensing/deal-flow events, clinical efficacy benchmarks by route (20-28% injectable vs 12-14% oral mean weight loss) and real-world persistence measures (~50% discontinuation within six months, cost cited in 43-68% of cases).

Open buyer room →

Sample

Brickroad customers

Sample this dataset before you buy it.

Your sourcing agent asks Sleuthinsights and files the sample in your catalog — private to you.

Start 7-day trialNothing is charged until the trial ends.

Coverage

Universe, instruments and categories.

Industry: PharmaceuticalsFinancial Exchanges & Data
Instruments: equities
Categories

Dataset card

Type: not stated
Format: Structured program-level records in a maintained internal database (stage, developer, geography, mechanism/target pairing, route, indication, sales, deal events) published externally as long-form analytical reports with charts and quarterly editions; no public API or bulk download is advertised
Volume: 628 active GLP-1 and metabolic programs at the August 2026 cut with full stage, geography, mechanism-pairing and route classification; 124 distinct mechanism pairings; 181 cardio-renal-metabolic incretin programs; brand-level sales series across at least six named products with prior-year comparatives; plus parallel class-level datasets in the publisher's other franchises (biopharma duopolies, obesity access), implying a multi-thousand-program cross-therapeutic universe and multiple quarterly editions per year
Users: N/A — subscription intelligence service sold to institutional subscribers (biopharma strategy/BD and buy-side), not a registered-user consumer product; no seat or subscriber count is published
History: 3 years
Update frequency: not stated
Growth: Active — Q3 2026 edition of the GLP-1/metabolic report published on an August 2026 data cut, an ongoing series of interlinked analytical reports, and a stated forward view (quality-of-weight-loss benchmark expected to dominate by 2027) that presupposes continued quarterly coverage
Launched: ~2023-2024 (San Francisco venture-stage company with a 21-person team; the publisher states it has tracked the obesity value shift 'since' an earlier analytical inflection, and the corporate record places its formation in the 2023-2024 window)
Delivery: not stated
Entity mapping: not stated
Sample: not stated
Point-in-time: not stated
Licence: not stated

supplier index read from their site